BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology 2019;157:1007-1018.e7. [PMID: 31279871 DOI: 10.1053/j.gastro.2019.06.038] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Kong L, Pokatayev V, Lefkovith A, Carter GT, Creasey EA, Krishna C, Subramanian S, Kochar B, Ashenberg O, Lau H, Ananthakrishnan AN, Graham DB, Deguine J, Xavier RJ. The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon. Immunity 2023:S1074-7613(23)00012-2. [PMID: 36720220 DOI: 10.1016/j.immuni.2023.01.002] [Reference Citation Analysis]
2 Heidbreder K, Sommer K, Wiendl M, Müller TM, Atreya I, Hildner K, Neurath MF, Zundler S. Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1040775] [Reference Citation Analysis]
3 Steenholdt C, Lorentsen RD, Petersen PN, Brynskov J. Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease. J Gastroenterol Hepatol 2022. [PMID: 36582016 DOI: 10.1111/jgh.16099] [Reference Citation Analysis]
4 Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 2022;71:2587-97. [PMID: 35927032 DOI: 10.1136/gutjnl-2021-326562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Abreu MT, Davies JM, Quintero MA, Delmas A, Diaz S, Martinez CD, Venables T, Reich A, Crynen G, Deshpande AR, Kerman DH, Damas OM, Fernandez I, Santander AM, Pignac-Kobinger J, Burgueno JF, Sundrud MS. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy. Inflamm Bowel Dis 2022;28:1800-12. [PMID: 35993552 DOI: 10.1093/ibd/izac151] [Reference Citation Analysis]
6 Iacucci M, Jeffery L, Acharjee A, Grisan E, Buda A, Nardone OM, Smith SCL, Labarile N, Zardo D, Ungar B, Hunter S, Mao R, Cannatelli R, Shivaji UN, Parigi TL, Reynolds GM, Gkoutos GV, Ghosh S. Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. Inflamm Bowel Dis 2022:izac233. [PMID: 36378498 DOI: 10.1093/ibd/izac233] [Reference Citation Analysis]
7 Leenhardt R, Koulaouzidis A, Histace A, Baatrup G, Beg S, Bourreille A, de Lange T, Eliakim R, Iakovidis D, Dam Jensen M, Keuchel M, Margalit Yehuda R, McNamara D, Mascarenhas M, Spada C, Segui S, Smedsrud P, Toth E, Tontini GE, Klang E, Dray X, Kopylov U. Key research questions for implementation of artificial intelligence in capsule endoscopy. Therap Adv Gastroenterol 2022;15:17562848221132683. [PMID: 36338789 DOI: 10.1177/17562848221132683] [Reference Citation Analysis]
8 Roseira J, Santiago M, Estevinho MM, Moreira P, Alves C, Danese S, Peyrin-Biroulet L, Dignass A, Feakins R, Magro F. Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis. Inflamm Bowel Dis 2022:izac203. [PMID: 36250778 DOI: 10.1093/ibd/izac203] [Reference Citation Analysis]
9 Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V; CORE-IBD Collaborators. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology 2022;163:950-64. [PMID: 35788348 DOI: 10.1053/j.gastro.2022.06.068] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li X, Zhong Y, Yuan C, Lin J, Shen X, Guo M, Lu B, Meng J, Wang Y, Zhang N, Luo Z, Hu G, Mao R, Chen M, Sun C, Li Z, Cao Q, Chen B, Chen Z, Huang B, Feng S. Identifying patients with Crohn's disease at high risk of primary nonresponse to infliximab using a radiomic‐clinical model. Int J of Intelligent Sys. [DOI: 10.1002/int.23066] [Reference Citation Analysis]
11 Xu W, Hua Z, Wang Y, Gu Y, Zhong J, Cui L, Du P. The endoscopic prediction model of simple endoscopic score for Crohn’s disease (SES-CD) as an effective predictor of intestinal obstruction in Crohn’s disease: A multicenter long-term follow-up study. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.984029] [Reference Citation Analysis]
12 Pérez-Jeldres T, Pizarro B, Ascui G, Orellana M, Cerda-Villablanca M, Alvares D, de la Vega A, Cannistra M, Cornejo B, Baéz P, Silva V, Arriagada E, Rivera-Nieves J, Estela R, Hernández-Rocha C, Álvarez-Lobos M, Tobar F. Ethnicity influences phenotype and clinical outcomes: Comparing a South American with a North American inflammatory bowel disease cohort. Medicine (Baltimore) 2022;101:e30216. [PMID: 36086782 DOI: 10.1097/MD.0000000000030216] [Reference Citation Analysis]
13 Gordon BL, Galati JS, Yang S, Longman RS, Lukin D, Scherl EJ, Battat R. Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease. World J Gastroenterol 2022; 28(33): 4834-4845 [DOI: 10.3748/wjg.v28.i33.4834] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Marion L, Amélie B, Zoubir D, Guillaume C, Elise MS, Hedia B, Margaux LS, Aude M, Camille BR. Histological Indices and Risk of Recurrence in Crohn's Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission. Inflamm Bowel Dis 2022;28:1395-404. [PMID: 35429159 DOI: 10.1093/ibd/izac074] [Reference Citation Analysis]
15 Xu Z, Chen H, Chu H, Shen X, Deng C, Sun N, Wu H. Diagnosis and subtype classification on serum peptide fingerprints by mesoporous polydopamine with built-in metal-organic framework. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.107829] [Reference Citation Analysis]
16 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2022;54:1168-78. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Romero RK, Magro DO, Queiroz NSF, Damião AOMC, Teixeira FV, Nones RB, Sassaki LY, Saad-hossne R, Kotze PG. Perception and clinical decisions from inflammatory bowel diseases’ specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterología y Hepatología (English Edition) 2022;45:499-506. [DOI: 10.1016/j.gastre.2021.09.009] [Reference Citation Analysis]
18 Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. Am J Gastroenterol 2022;117:1106-17. [PMID: 35435862 DOI: 10.14309/ajg.0000000000001795] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Reinisch W, Serone A, Hébuterne X, Kühbacher T, Kłopocka M, Roblin X, Brodbeck J, Etchevers K, Galien R, Grant E, Tasset C, Yoon OK, Zaboli S, Vermeire S. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. Tissue Barriers 2022;:2088961. [PMID: 35762272 DOI: 10.1080/21688370.2022.2088961] [Reference Citation Analysis]
20 Pinton P. Prediction of vedolizumab treatment outcomes by machine learning. J Biopharm Stat 2022;:1-3. [PMID: 35763418 DOI: 10.1080/10543406.2022.2065501] [Reference Citation Analysis]
21 Wu S, Zeng L, Li W, Wu YT, Jing JG, Zhuang H, Wang YF. The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease. Dig Liver Dis 2022;54:763-70. [PMID: 34991975 DOI: 10.1016/j.dld.2021.12.009] [Reference Citation Analysis]
22 Vieujean S, Caron B, Jairath V, Benetos A, Danese S, Louis E, Peyrin-Biroulet L. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev 2022;3:e356-66. [PMID: 36098310 DOI: 10.1016/S2666-7568(22)00060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wlazło M, Kierkuś J. Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature. JCM 2022;11:2004. [DOI: 10.3390/jcm11072004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Howard G, Weiner D, Bar-Or I, Levine A. Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children. Eur J Gastroenterol Hepatol 2022;34:372-4. [PMID: 34034281 DOI: 10.1097/MEG.0000000000002203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022;162:1456-1475.e1. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Volkers A, Bossuyt P, de Jong J, Pouillon L, Gecse K, Duijvestein M, Ponsioen C, D'Haens G, Löwenberg M. Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study. Scand J Gastroenterol 2022;57:439-45. [PMID: 34968158 DOI: 10.1080/00365521.2021.2018491] [Reference Citation Analysis]
27 Akbar A, Orchard T, Powell N, Selinger C, Tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol 2022;13:490-6. [PMID: 36250175 DOI: 10.1136/flgastro-2021-101995] [Reference Citation Analysis]
28 Egozi A, Olaloye O, Werner L, Silva T, Mccourt B, Pierce RW, An X, Wang F, Chen K, Pober JS, Shoval D, Itzkovitz S, Konnikova L. Single cell atlas of the neonatal small intestine with necrotizing enterocolitis.. [DOI: 10.1101/2022.03.01.482508] [Reference Citation Analysis]
29 Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn'´s disease: Ddoes location makes a difference in therapy efficacy? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100097] [Reference Citation Analysis]
30 Danese S, Kamble P, Yang J, Le Moine J, Khan S, Hawe E, Agboton C, Wang S, Irving PM. Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease. GastroHep 2022;2022:1-12. [DOI: 10.1155/2022/6975416] [Reference Citation Analysis]
31 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fernàndez-Clotet A, Sapena V, Capozzi N, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J, Rimola J. Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. Eur Radiol 2022. [PMID: 35031844 DOI: 10.1007/s00330-021-08392-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 Venkatapurapu SP, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R, Kumar K, Sato Y, Behar M, Offner P, Dwivedi G, Miyasaka H, Suzuki RK, Hamada AL, D'Alessandro PM, Fernandez J. A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther 2022;39:3225-47. [PMID: 35581423 DOI: 10.1007/s12325-022-02144-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kwapisz L, Bruining DH, Inoue A, Lee YS, Edwards PK, Holmes DR, Carter RE, Siegelman J, Fletcher JG. CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac003] [Reference Citation Analysis]
35 Belousova EA, Kozlov IG, Abdulganieva DI, Alexeeva OP, Gubonina IV, Lishchinskaya AA, Tarasova LV, Chashkova EY, Shapina MV, Shifrin OS, Shchukina OB. Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021). Alʹm klin med 2021;49:485-495. [DOI: 10.18786/2072-0505-2021-49-060] [Reference Citation Analysis]
36 Tse CS, Jairath V, Feagan BG, Sandborn WJ. Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. Curr Treat Options Gastro 2021;19:608-627. [DOI: 10.1007/s11938-021-00362-x] [Reference Citation Analysis]
37 Tao Y, Li H, Xu H, Tang W, Fan G, Yang X. Can the simplified magnetic resonance index of activity be used to evaluate the degree of activity in Crohn's disease? BMC Gastroenterol 2021;21:409. [PMID: 34711180 DOI: 10.1186/s12876-021-01987-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hyun HK, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement. Korean J Intern Med 2021. [PMID: 34695881 DOI: 10.3904/kjim.2021.233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Romero RK, Magro DO, Queiroz NSF, Damião AOMC, Teixeira FV, Nones RB, Sassaki LY, Saad-Hossne R, Kotze PG. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterol Hepatol 2021:S0210-5705(21)00296-X. [PMID: 34634427 DOI: 10.1016/j.gastrohep.2021.09.005] [Reference Citation Analysis]
40 Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. Front Immunol 2021;12:711217. [PMID: 34512631 DOI: 10.3389/fimmu.2021.711217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pierre N, Salée C, Vieujean S, Bequet E, Merli AM, Siegmund B, Meuwis MA, Louis E. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021;54:779-91. [PMID: 34297423 DOI: 10.1111/apt.16536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
44 Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2022;16:27-38. [PMID: 34402887 DOI: 10.1093/ecco-jcc/jjab133] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
45 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
46 Klemm N, Trasolini R, Chahal D, Donnellan F. Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis. Clin Res Hepatol Gastroenterol 2021;45:101604. [PMID: 33454238 DOI: 10.1016/j.clinre.2020.101604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Hanzel J, Dreesen E, Vermeire S, Löwenberg M, Hoentjen F, Bossuyt P, Clasquin E, Baert FJ, D'Haens GR, Mathôt R. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflamm Bowel Dis 2022;28:689-99. [PMID: 34137430 DOI: 10.1093/ibd/izab143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol 2021;6:659-67. [PMID: 34090579 DOI: 10.1016/S2468-1253(21)00096-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
49 Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum 2021;64:697-705. [PMID: 33315712 DOI: 10.1097/DCR.0000000000001881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
51 Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr 2021;180:3029-38. [PMID: 33880650 DOI: 10.1007/s00431-021-04063-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
53 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021;44:312-319. [DOI: 10.1016/j.gastre.2020.06.023] [Reference Citation Analysis]
54 Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(9): 886-907 [PMID: 33727776 DOI: 10.3748/wjg.v27.i9.886] [Reference Citation Analysis]
55 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
56 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
57 King JR, Grover Z, Irani N, Mclean-tooke A. Vedolizumab is safe and effective in the treatment of X-linked agammaglobulinemia–associated inflammatory bowel disease. The Journal of Allergy and Clinical Immunology: In Practice 2021;9:1006-7. [DOI: 10.1016/j.jaip.2020.11.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
59 Li XZ, Qiu Y, Jeffery L, Liu F, Feng R, He JS, Tan JY, Ye ZY, Lin SN, Ghosh S, Iacucci M, Chen MH, Mao R. Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Front Med (Lausanne) 2020;7:613475. [PMID: 33511147 DOI: 10.3389/fmed.2020.613475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 44.5] [Reference Citation Analysis]
61 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Coelho-Prabhu N, Kane S. Does Size Really Matter? Am J Gastroenterol 2021;116:84-5. [PMID: 33181520 DOI: 10.14309/ajg.0000000000001057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Lee SD, Singla A, Clark‐snustad K. Standard and modified vedolizumab dosing is effective in achieving clinical and endoscopic remission in moderate‐severe Crohn’s disease. GastroHep 2021;3:26-36. [DOI: 10.1002/ygh2.438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Pauwels RWM, van der Woude CJ, Erler NS, de Vries AC. Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therap Adv Gastroenterol 2020;13:1756284820979765. [PMID: 33488771 DOI: 10.1177/1756284820979765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
65 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
67 Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther 2020;52:1563-73. [PMID: 32886809 DOI: 10.1111/apt.16069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
68 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
69 Xu L, Shen J, Zheng Q. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease. Int J Colorectal Dis 2020;35:2019-26. [PMID: 32577870 DOI: 10.1007/s00384-020-03679-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Pan J, Fu D, Li Y, Wang Y, Lian G, Liu X. Body weight, serum albumin and food intolerance were linked to upper gastrointestinal Crohn's disease: a 7-year retrospective analysis. Ann Transl Med 2020;8:1370. [PMID: 33313115 DOI: 10.21037/atm-20-2212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
72 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
73 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Perez-Jeldres T, Yarur A, Behm B, Dulai PS, Patel D, Bamias G, Rivera-Nieves J. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. J Crohns Colitis 2020;14:1364-77. [PMID: 32239151 DOI: 10.1093/ecco-jcc/jjaa067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
74 Gamliel A, Werner L, Pinsker M, Salamon N, Weiss B, Shouval DS. Circulating α4β7+ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire. Clin Exp Gastroenterol 2020;13:439-47. [PMID: 33061522 DOI: 10.2147/CEG.S271565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
75 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020;18:2518-2525.e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
76 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
77 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
78 Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing. Inflamm Bowel Dis 2020;26:1131-43. [PMID: 32232386 DOI: 10.1093/ibd/izaa045] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
79 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study. Scand J Gastroenterol 2020;55:907-16. [PMID: 32657179 DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Zingone F, Barberio B, Compostella F, Girardin G, D'Incà R, Marinelli C, Marsilio I, Lorenzon G, Savarino EV. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therap Adv Gastroenterol 2020;13:1756284820936536. [PMID: 32695231 DOI: 10.1177/1756284820936536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
81 Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E2126. [PMID: 32640680 DOI: 10.3390/jcm9072126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Arebi N. Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice? Lancet Gastroenterol Hepatol 2020;5:877-8. [PMID: 32619414 DOI: 10.1016/S2468-1253(20)30234-X] [Reference Citation Analysis]
83 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
84 Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 2020;5:819-28. [PMID: 32553149 DOI: 10.1016/S2468-1253(20)30188-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 18.0] [Reference Citation Analysis]
85 Sulz MC, Duetschler J, Seibold F. Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag. Schweiz Gastroenterol 2020;1:51-64. [DOI: 10.1007/s43472-020-00009-9] [Reference Citation Analysis]
86 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
87 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
88 Pagnini C, Di Paolo MC, Giordano M, Graziani MG. Histologic disease activity control as a therapeutic target in Crohn's disease patients: A word of caution. Dig Liver Dis 2020;52:591-2. [PMID: 32057685 DOI: 10.1016/j.dld.2020.01.003] [Reference Citation Analysis]
89 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
90 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointest Endosc 2020;91:733-45. [PMID: 31786161 DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
91 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
92 Macaluso FS, Castiglione F, Rispo A, Orlando A. The VERSIFY Trial: What About Ultrasound Assessment? Gastroenterology 2020;158:1176-7. [PMID: 31836531 DOI: 10.1053/j.gastro.2019.11.298] [Reference Citation Analysis]
93 Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther 2020;51:553-64. [PMID: 31867766 DOI: 10.1111/apt.15609] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
94 Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. J Crohns Colitis 2020;14:1066-73. [PMID: 32060515 DOI: 10.1093/ecco-jcc/jjaa027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
95 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
96 Costrini NV. Clearing of the Clouds in Inflammatory Bowel Disease Management. Dig Dis Sci 2020;65:3411-7. [PMID: 33009978 DOI: 10.1007/s10620-020-06635-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol 2020;55:291-306. [PMID: 31836930 DOI: 10.1007/s00535-019-01647-w] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
98 Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Gonczi L, Bessissow T, Lakatos PL. Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn's Disease. Gastroenterology 2019;157:925-7. [PMID: 31356804 DOI: 10.1053/j.gastro.2019.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]